Hyperthermic Intrathoracic Chemoperfusion for Malignant Pleural Mesothelioma: Systematic Review and Meta-Analysis
Malignant pleural mesothelioma (MPM) is an aggressive malignancy of the pleural lining with exceptionally poor survival. Hyperthermic intrathoracic chemoperfusion (HITHOC) is commonly used with surgery in limited disease. However, data on its effect on survival are limited. In this systematic review...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-07-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/14/3637 |
| _version_ | 1797527429567217664 |
|---|---|
| author | Tommi Järvinen Juuso Paajanen Ilkka Ilonen Jari Räsänen |
| author_facet | Tommi Järvinen Juuso Paajanen Ilkka Ilonen Jari Räsänen |
| author_sort | Tommi Järvinen |
| collection | DOAJ |
| description | Malignant pleural mesothelioma (MPM) is an aggressive malignancy of the pleural lining with exceptionally poor survival. Hyperthermic intrathoracic chemoperfusion (HITHOC) is commonly used with surgery in limited disease. However, data on its effect on survival are limited. In this systematic review and meta-analysis, we analyzed a total of 11 observational articles. HITHOC was compared to control arm that did not receive HITHOC in three studies including 762 patients. The pooled analysis of these studies revealed an SMD of 0.24, with 95% CI of 0.06–0.41 favoring the HITHOC group, reaching statistical significance. The survival effect of HITHOC in epithelioid MPM vs. non-epithelioid MPM was analyzed in four studies. Pooled analysis showed an SMD of 0.79 (95% CI = 0.48–1.10) favoring epithelioid MPM. Based on available data, there seems to be a benefit with HITHOC in regards to overall survival in the treatment of all mesothelioma patients. Multicenter randomized controlled trials are needed to validate and standardize this treatment approach. |
| first_indexed | 2024-03-10T09:42:47Z |
| format | Article |
| id | doaj.art-11a0154e48344e339eca965a076ac53a |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T09:42:47Z |
| publishDate | 2021-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-11a0154e48344e339eca965a076ac53a2023-11-22T03:26:39ZengMDPI AGCancers2072-66942021-07-011314363710.3390/cancers13143637Hyperthermic Intrathoracic Chemoperfusion for Malignant Pleural Mesothelioma: Systematic Review and Meta-AnalysisTommi Järvinen0Juuso Paajanen1Ilkka Ilonen2Jari Räsänen3Department of General Thoracic and Esophageal Surgery, Heart and Lung Center, Helsinki University Hospital, 00029 Helsinki, FinlandDepartment of Pulmonary Medicine, Heart and Lung Center, Helsinki University Hospital and University of Helsinki, 00029 Helsinki, FinlandDepartment of General Thoracic and Esophageal Surgery, Heart and Lung Center, Helsinki University Hospital, 00029 Helsinki, FinlandDepartment of General Thoracic and Esophageal Surgery, Heart and Lung Center, Helsinki University Hospital, 00029 Helsinki, FinlandMalignant pleural mesothelioma (MPM) is an aggressive malignancy of the pleural lining with exceptionally poor survival. Hyperthermic intrathoracic chemoperfusion (HITHOC) is commonly used with surgery in limited disease. However, data on its effect on survival are limited. In this systematic review and meta-analysis, we analyzed a total of 11 observational articles. HITHOC was compared to control arm that did not receive HITHOC in three studies including 762 patients. The pooled analysis of these studies revealed an SMD of 0.24, with 95% CI of 0.06–0.41 favoring the HITHOC group, reaching statistical significance. The survival effect of HITHOC in epithelioid MPM vs. non-epithelioid MPM was analyzed in four studies. Pooled analysis showed an SMD of 0.79 (95% CI = 0.48–1.10) favoring epithelioid MPM. Based on available data, there seems to be a benefit with HITHOC in regards to overall survival in the treatment of all mesothelioma patients. Multicenter randomized controlled trials are needed to validate and standardize this treatment approach.https://www.mdpi.com/2072-6694/13/14/3637malignant pleural mesotheliomahyperthermic intrathoracic chemoperfusion |
| spellingShingle | Tommi Järvinen Juuso Paajanen Ilkka Ilonen Jari Räsänen Hyperthermic Intrathoracic Chemoperfusion for Malignant Pleural Mesothelioma: Systematic Review and Meta-Analysis Cancers malignant pleural mesothelioma hyperthermic intrathoracic chemoperfusion |
| title | Hyperthermic Intrathoracic Chemoperfusion for Malignant Pleural Mesothelioma: Systematic Review and Meta-Analysis |
| title_full | Hyperthermic Intrathoracic Chemoperfusion for Malignant Pleural Mesothelioma: Systematic Review and Meta-Analysis |
| title_fullStr | Hyperthermic Intrathoracic Chemoperfusion for Malignant Pleural Mesothelioma: Systematic Review and Meta-Analysis |
| title_full_unstemmed | Hyperthermic Intrathoracic Chemoperfusion for Malignant Pleural Mesothelioma: Systematic Review and Meta-Analysis |
| title_short | Hyperthermic Intrathoracic Chemoperfusion for Malignant Pleural Mesothelioma: Systematic Review and Meta-Analysis |
| title_sort | hyperthermic intrathoracic chemoperfusion for malignant pleural mesothelioma systematic review and meta analysis |
| topic | malignant pleural mesothelioma hyperthermic intrathoracic chemoperfusion |
| url | https://www.mdpi.com/2072-6694/13/14/3637 |
| work_keys_str_mv | AT tommijarvinen hyperthermicintrathoracicchemoperfusionformalignantpleuralmesotheliomasystematicreviewandmetaanalysis AT juusopaajanen hyperthermicintrathoracicchemoperfusionformalignantpleuralmesotheliomasystematicreviewandmetaanalysis AT ilkkailonen hyperthermicintrathoracicchemoperfusionformalignantpleuralmesotheliomasystematicreviewandmetaanalysis AT jarirasanen hyperthermicintrathoracicchemoperfusionformalignantpleuralmesotheliomasystematicreviewandmetaanalysis |